Generium is a leading full-cycle scientific and manufacturing company in the Russian pharmaceutical market, specializing in the orphan drug segment. With its own R&D park, Generium has the capacity to develop any biotechnological drug from molecule creation to industrial production. Collaborating with top biotechnology companies and scientific institutes worldwide, Generium conducts research on individual medicines.

Its production facility adheres strictly to international GMP standards and is capable of manufacturing a diverse range of biotechnological drugs and biomedical cell products. Generium's mission is to save lives and improve people's health through their ideas and developments. Some of their notable products include Sputnik V®, Elizarium®, Glurazim®, Tigraza®, Genolar®, Rezeliza®, and Infibeta®.

With a commitment to quality and safety, Generium is dedicated to ensuring the well-being of patients and healthcare professionals